Tumor Spectrum and Temporal Cancer Trends in adult carriers of Li-Fraumeni syndrome: Implications for Personalized Screening Strategies in TP53 R337H carriers
GALANTE, P. A. F.; Guardia, G. D. A.; Pisani, J.; Sandoval, R.; Barros Filho, M. d. C.; Gifoni, A. C. V. C.; Patrao, D. F. D. C.; Ashton-Prolla, P.; Vasconcellos, V. F.; Freycon, C.; Levine, A.; Hainaut, P.; Achatz, M. I.
Show abstract
BackgroundLi-Fraumeni Syndrome (LFS) is a predisposition associated with early onset malignant tumors caused by germline pathogenic variants in the TP53 gene. Although rare worldwide, LFS is prevalent in Southern Brazil due to a founder pathogenic variant, c.1010G>A, p.Arg337His (R337H), discovered through its association with risk of childhood adrenal cortical carcinoma. MethodsHere, we have analyzed tumor patterns, cancer risk, sex differences and temporal tumor trends in a cohort of 303 adult R337H carriers and we have compared them with those of 405 adult carriers of other TP53 variants typical of LFS. FindingsCompared to the latter, R337H carriers had a lower cumulative risk of developing cancer (54% for R337H vs 78% for other TP53 variants at age 50 years). Female R337H carriers were at a higher risk than males (65% vs 30% at age 50 years) and had a higher risk of developing a second primary cancer, underscoring a strong sex bias not observed in carriers of other variants. The most common cancers were breast (75%), soft tissue sarcoma (9%) and lung cancer (8%) in females, and soft tissue sarcoma (30%), prostate (13%) and lung cancer (12%) in males. Common second malignancies were breast cancer in females and lung cancer in males. InterpretationsOverall, this study confirms that R337H is associated with a lifetime risk of multiple cancers of the LFS spectrum but with incomplete penetrance, particularly in males. Our findings suggest that R337H carriers would benefit from adapted lifetime and surveillance strategies for risk reduction. FundingSao Paulo Research Foundation and Hospital Sirio-Libanes.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Free testosterone and malignant melanoma risk in men: prospective analyses of testosterone and SHBG with 19 cancers in men and postmenopausal women UK Biobank 92%
- Cumulative COVID-19 incidence, mortality, and prognosis in cancer survivors: a population-based study in Reggio Emilia, Northern Italy 92%
- Prelude to Malignancy: A Gene Expression Signature in Normal Mammary Gland from Breast Cancer Patients Suggests Pre-tumorous Alterations and Is Associated with Adverse Outcomes 92%
Similar papers in this journal
- Hereditary haemochromatosis beyond liver cancer: increased risk of prostate cancer during an 11-year follow-up 94%
- Genetic analysis of functional rare germline variants across 9 cancer types from the DiscovEHR study 92%
- Cancer incidence and mortality estimates in Arab countries in 2018: A GLOBOCAN data analysis 92%
Similar papers in this journal
- MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation 91%
- CRISPR targeting of FOXL2 c.402C>G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti-tumoral compounds 90%
- Molecular diagnosis and prognosis of cancers of unknown-primary (CUPs): progress from a microRNA-based droplet digital PCR assay 90%
Similar papers in this journal
- Prevalence of pathogenic variants in DNA damage response genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer 93%
- New C3H KitN824K/WT cancer mouse model develops late-onset malignant mammary tumors with high penetrance 92%
- Metastasis is altered through multiple processes regulated by the E2F1 transcription factor 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.